• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

    6/23/25 8:00:00 AM ET
    $LAZ
    $SNN
    Investment Managers
    Finance
    Industrial Specialties
    Health Care
    Get the next $LAZ alert in real time by email

    Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. 



    As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. 

    Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D. 

    Following that, Ajay served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE:LAZ) where he was the Global Head of Medical Technology, Diagnostics and Tools. More recently, Ajay founded and led Bluish Capital, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets.

    Ajay has bachelor's degrees in Physics and Computer Science from Angelo State University, and both a master's degree and a doctorate in Molecular Biophysics and Biochemistry from Yale University. 

    Deepak Nath, Chief Executive Officer, commented: "Ajay's unique blend of scientific rigor, strategic insight, business development, integrations, and operational excellence, combined with his entrepreneurial leadership style, makes him exceptionally well-suited to help shape our future. We are pleased to have him join our leadership team at this exciting time for the company."

    - ends –



    Enquiries



    Investors
     
    Andrew Swift+44 (0) 1923 477433
    Smith+Nephew 
      
    Media 
    Charles Reynolds +44 (0) 1923 477314
    Smith+Nephew 
      
    Susan Gilchrist / Ayesha Bharmal+44 (0) 20 7404 5959
    Brunswick 

     

    About Smith+Nephew

    Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

    Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

    For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

      

    Forward-looking Statements

    This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.



    ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.



    Primary Logo

    Get the next $LAZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAZ
    $SNN

    CompanyDatePrice TargetRatingAnalyst
    Smith & Nephew SNATS Inc.
    $SNN
    10/14/2025$37.50Outperform → Mkt Perform
    Bernstein
    Lazard Inc.
    $LAZ
    10/3/2025$56.00Market Perform
    BMO Capital Markets
    Lazard Inc.
    $LAZ
    8/25/2025$65.00Mkt Perform → Outperform
    Keefe Bruyette
    Smith & Nephew SNATS Inc.
    $SNN
    4/25/2025Buy → Hold
    HSBC Securities
    Lazard Inc.
    $LAZ
    4/7/2025$56.00 → $33.00Equal-Weight → Underweight
    Morgan Stanley
    Smith & Nephew SNATS Inc.
    $SNN
    3/12/2025Buy → Neutral
    UBS
    Lazard Inc.
    $LAZ
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    Lazard Inc.
    $LAZ
    12/20/2024$65.00 → $57.00Outperform → Mkt Perform
    Keefe Bruyette
    More analyst ratings

    $LAZ
    $SNN
    SEC Filings

    View All

    Lazard Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lazard, Inc. (0001311370) (Filer)

    10/23/25 6:30:24 AM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

    10/22/25 11:38:24 AM ET
    $SNN
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

    10/16/25 9:02:26 AM ET
    $SNN
    Industrial Specialties
    Health Care

    $LAZ
    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Shevelenko Dmitry

    4 - Lazard, Inc. (0001311370) (Issuer)

    9/18/25 4:30:18 PM ET
    $LAZ
    Investment Managers
    Finance

    CEO & Chairman Orszag Peter Richard converted options into 64,949 shares, returned $1,083,171 worth of shares to the company (19,485 units at $55.59) and sold $1,756,573 worth of shares (32,475 units at $54.09), increasing direct ownership by 8% to 183,274 units (SEC Form 4)

    4 - Lazard, Inc. (0001311370) (Issuer)

    9/17/25 8:06:50 PM ET
    $LAZ
    Investment Managers
    Finance

    CEO of Asset Management Russo Evan L gifted 15,000 shares and sold $4,240,260 worth of shares (75,000 units at $56.54), decreasing direct ownership by 28% to 227,915 units (SEC Form 4)

    4 - Lazard, Inc. (0001311370) (Issuer)

    9/11/25 7:27:29 PM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lazard Reports Third Quarter and Nine Month 2025 Results

    Record firmwide adjusted net revenue for the third quarter of $725 million, up 12% year-over-year Record Financial Advisory adjusted net revenue of $1.3 billion for the first nine months of 2025, with 20 Managing Directors hired year-to-date to support long-term growth Record Asset Management inflows for the third quarter and first nine months of the year, with positive net flows of $1.6 billion and total AUM up 17% year-to-date Lazard, Inc. (NYSE:LAZ) today reported net revenue of $748 million and record adjusted net revenue1 of $725 million for the quarter ended September 30, 2025. For the first nine months of 2025, Lazard reported net revenue of $2,192 million and adjusted net

    10/23/25 6:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in September

    Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on November 24, 2025, to shareholders of record on November 12, 2025. The ex-dividend date is November 12, 2025. The Fund will pay a previously declared distribution today, October 22, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income,

    10/22/25 6:00:00 PM ET
    $LAZ
    $LGI
    Investment Managers
    Finance

    Lazard Declares Quarterly Dividend of $0.50 Per Share

    Lazard, Inc. (NYSE:LAZ) today announced that its Board of Directors has voted to declare a quarterly dividend of $0.50 per share on its outstanding common stock. The dividend is payable on November 14, 2025, to stockholders of record on November 3, 2025. About Lazard Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corpor

    10/22/25 4:15:00 PM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Smith & Nephew downgraded by Bernstein with a new price target

    Bernstein downgraded Smith & Nephew from Outperform to Mkt Perform and set a new price target of $37.50

    10/14/25 8:42:59 AM ET
    $SNN
    Industrial Specialties
    Health Care

    BMO Capital Markets initiated coverage on Lazard with a new price target

    BMO Capital Markets initiated coverage of Lazard with a rating of Market Perform and set a new price target of $56.00

    10/3/25 8:41:45 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Lazard from Mkt Perform to Outperform and set a new price target of $65.00

    8/25/25 8:08:17 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    $SNN
    Leadership Updates

    Live Leadership Updates

    View All

    Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage

    Lazard, Inc. (NYSE:LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard's Financial Sponsors Group, to further strengthen the firm's presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset ma

    10/20/25 2:00:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Welcomes Cyrille Cotte as Managing Director and Head of Insurance for European Financial Institutions

    Lazard, Inc. (NYSE:LAZ) today announced the appointment of Cyrille Cotte as Managing Director and Head of Insurance for its European Financial Institutions Group (FIG), based in London and working across Europe with regional Co-Heads of Financial Services Coverage Nick Millar and Corso Bavagnoli. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930678445/en/Cyrille Cotte Cyrille joins Lazard from Evercore, where he was a Partner and Senior Managing Director in the European Financial Institutions Group. Over his career, he has focused on advising a broad range of insurers and other financial services firms on mergers, acquisitio

    10/1/25 2:00:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Hires Geoffrey Porges to Healthcare Advisory Group

    Lazard announced today that Dr. Geoffrey Porges has joined the firm as Managing Director in the Healthcare Advisory Group, advising on transactions across diversified biopharmaceuticals. "We are thrilled to welcome Geoffrey to Lazard," said David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare. "His deep understanding of the biopharmaceutical industry's strategic and financial landscape, coupled with his ability to help companies translate scientific innovation into actionable business strategies, will empower our clients to strengthen their competitive positions, capitalize on growth opportunities, and build resilient companies in a challenging geopolitical an

    9/18/25 7:00:00 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    $SNN
    Financials

    Live finance-specific insights

    View All

    Lazard Reports Third Quarter and Nine Month 2025 Results

    Record firmwide adjusted net revenue for the third quarter of $725 million, up 12% year-over-year Record Financial Advisory adjusted net revenue of $1.3 billion for the first nine months of 2025, with 20 Managing Directors hired year-to-date to support long-term growth Record Asset Management inflows for the third quarter and first nine months of the year, with positive net flows of $1.6 billion and total AUM up 17% year-to-date Lazard, Inc. (NYSE:LAZ) today reported net revenue of $748 million and record adjusted net revenue1 of $725 million for the quarter ended September 30, 2025. For the first nine months of 2025, Lazard reported net revenue of $2,192 million and adjusted net

    10/23/25 6:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in September

    Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on November 24, 2025, to shareholders of record on November 12, 2025. The ex-dividend date is November 12, 2025. The Fund will pay a previously declared distribution today, October 22, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income,

    10/22/25 6:00:00 PM ET
    $LAZ
    $LGI
    Investment Managers
    Finance

    Lazard Declares Quarterly Dividend of $0.50 Per Share

    Lazard, Inc. (NYSE:LAZ) today announced that its Board of Directors has voted to declare a quarterly dividend of $0.50 per share on its outstanding common stock. The dividend is payable on November 14, 2025, to stockholders of record on November 3, 2025. About Lazard Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corpor

    10/22/25 4:15:00 PM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lazard Inc.

    SC 13G - Lazard, Inc. (0001311370) (Subject)

    11/8/24 2:17:07 PM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

    SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

    7/9/24 12:00:10 PM ET
    $SNN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Lazard LTD. Lazard LTD. (Amendment)

    SC 13G/A - Lazard, Inc. (0001311370) (Subject)

    2/14/24 9:41:26 AM ET
    $LAZ
    Investment Managers
    Finance